



THE IMPACT OF MAST CELLS IN NEUROIMMUNOLOGY AND CANCER

F. Pandolfi*

Allergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, Rome, Italy.

*Correspondence to:

Franco Pandolfi,
Allergy and Clinical Immunology,
Fondazione Policlinico Universitario A. Gemelli IRCCS,
Catholic University,
00168 Rome, Italy.
e-mail: franco.pandolfi@unicatt.it

ABSTRACT

The nervous system and immune system are connected by bidirectional pathways, and behavioral influences can have effects on immune functions. Immune system stress can have regulatory effects in neuroinflammation, allergic reactions, cancer growth, and other conditions. Additionally, psychological stress can aggravate different conditions such as atopic dermatitis, rhinitis, and asthma. Mast cells (MCs) are immune cells derived from the myeloid lineage which migrate to peripheral tissues to differentiate and mature. They play an important role in the innate and adaptive immune responses, where the physiological and pathological aspects are regulated by the activation and degranulation of MCs. This includes immune responses such as those involved in infection, allergic disease, stress, and tumor growth. MCs cells are ubiquitous in the body, and have a close anatomical and functional relationship with neurons and neuronal processes in the central and peripheral nervous systems. MCs are rich sources of biologically active preformed mediators, which are contained in secretory granules. These cells can differentially and selectively release their mediators, and utilizing this selective release process in treatment could offer therapeutic opportunities for cancer, hypersensitivity reactions, and neuroinflammation.

KEYWORDS: *mast cell, neuroimmunology, neuroinflammation, immune, cancer*

INTRODUCTION

There is evidence indicating that the nervous system, which communicates with the whole organism, can regulate cancer growth directly or through the immune system. Published studies have indicated that stress may have a permissive effect on cancer growth (1-4), neuroinflammation, and other conditions, and it has now been established that stress can produce definitive changes in the make-up and function of the immune system (5,6). Moreover, there is much discussion concerning psychoneuroimmunoendocrinology that studies the interplay between the psyche, neural, and endocrine functions and immune responses, and the applications of these effects on the immune response and cell proliferation (7-10).

Allergic reactions have been shown to have neuropsychologic elements that comprise a close association between the immune system and the nervous system (11). These cases involve a disease pathophysiology that cannot be accounted for solely by elevated levels of immunoglobulin E (IgE) and antigen (Ag). Different studies have shown the psychoneuroimmunoendocrinologic association in allergic reactions such as atopic dermatitis (AD), rhinitis, and asthma,

Received: 21 July, 2023
Accepted: 28 August, 2023

2974-6345 (2023)

Copyright © by BIOLIFE

This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder. Unauthorized reproduction may result in financial and other penalties. Disclosure: all authors report no conflicts of interest relevant to this article.

which can be induced or aggravated by compounds of the nervous and endocrine systems and are linked to psychological stress (12-16).

Mast cells (MCs) are immune and inflammatory cells that play an important role in the innate and adaptive immune systems. Additionally, they are the main effector cells implicated in allergic or anaphylactic reactions. Paul Ehrlich first identified these cells in 1878 using a staining process to show the multitude of granules they contained (17). MCs are derived from immature pluripotent hematopoietic progenitors in the bone marrow, and then migrate through the vasculature system to reach peripheral tissues where they differentiate and mature in a tissue-specific manner (18-21). The activation and degranulation of MCs regulates many physiological and pathological aspects, including the initiation and the continuation of inflammatory responses, including those in the central nervous system (CNS).

These cells are ubiquitous in the body and their membrane-bound secretory granules contain biologically active preformed mediators (22). During allergic immune reactions, MCs are triggered by IgE and Ag, as well as diverse neuropeptides. MCs are localized in association with the CNS and the peripheral nervous system, where they are directly innervated and have a close anatomical and functional relationship with neurons and neuronal processes (23). For this, it is suggested that MCs also have a close association with neurotransmitters and neuropeptides where there is likely bidirectional regulation.

MCs are located around the vasculature and are present in brain tissue, particularly in the hippocampus, thalamus, and hypothalamus (24). MC mediators may influence the physiopathology of the body, including the response to stress by regulating the levels of peptide hormones available in the hypothalamic-pituitary axis and the production of proinflammatory and antiinflammatory molecules.

MCs are involved in the induction and development of immune responses in response to infection, allergic disease, and, although the mechanisms are still unclear, stress and tumor growth. The tumor microenvironment is made up of fibroblasts, adipose cells, immune-inflammatory cells, the extracellular matrix, and blood and vascular networks (25). It has been shown independently both *in vitro* and *in vivo* that MCs undergo differential or selective release of their mediators, a process that occurs without degranulation that might operate using vesicular shuttles utilizing specific mediator binding proteins (26-28). Inducing the selective release of MC mediators or selectively inhibiting MC degranulation after appropriate stimulation could result in either enhancement or suppression of tumor growth. Such a process could enhance science's understanding of the pathophysiology of cancer, type I and VI hypersensitivity reactions, and neuroinflammation, and could provide new therapeutic opportunities.

Mast cells and neuroinflammation

Neuroinflammation is a hallmark of neurodegenerative diseases, with MCs playing an important role in this process. The immune system initiates the protective response of inflammation to repair and heal damage inflicted by injury, bacteria, or other harmful insults. Neuroinflammation is the inflammatory response that occurs in the CNS which can be detrimental if it is prolonged. Chronic neuroinflammation can inhibit regeneration and lead to brain injury (29), and it is a characteristic feature of diseases such as Alzheimer's disease (AD) (30,31), Parkinson's disease (PD) (32), and amyotrophic lateral sclerosis (ALS) (33). Interactions between glial cells, immune cells, and neurons can produce and sustain neuroinflammation. Microglia and astrocytes mediate innate immune responses in the brain that can be activated by proinflammatory stimuli that are released from immune cells such as MCs. MCs produce various inflammatory mediators including histamine, proteases, growth factors, chemokines, and cytokines. MCs are normally found in low numbers in the brain (34), but increased numbers of these cells have been observed during trauma, stress, infection, and in some CNS diseases such as stroke (35) and multiple sclerosis (36,37). MCs participate in neuroinflammation by interacting with glial cells and neurons, and effecting blood-brain barrier (BBB) permeability and neurodegenerative processes such as neuronal death, excitotoxicity, and synaptic dysfunction (38).

Microglia and MCs can interact by complex unidirectional or bidirectional cross-communication. For example, tryptase released from MCs activates microglia (through PAR2 receptors) to release reactive oxygen species (ROS), tumor necrosis factor (TNF), and IL-6 (36,39). However, due to their prestored granule supply of mediatory substances such as immunomodulators, neuromodulators, proteases, growth factors, and amines, MCs can act quickly to injury and insult and are increasingly being considered as first-responders in the immune response in the CNS (40). MC degranulation releases gonadotropin hormone-releasing hormone (GnRH), monoamines, proteases including chymases, tryptases, carboxypeptidase, cytokines, and histamine (41,42), which exert effects on nearby cells (e.g. T cells) that enter the brain through the compromised BBB in states of infection and inflammation. Additionally, these MC-released compounds activate microglia, which go on to release pro-inflammatory cytokines that exacerbate the inflammatory state. Due to their close proximity, microglia and MCs interact and affect each other through paracrine mechanisms (38).

Finally, MCs may be involved in stress-related neuroinflammation and neurodegeneration. Chronic stress has been linked to neuroinflammation, which it seems to exacerbate, and increases the risk of neurodegenerative diseases such as AD (43, 44). During stress and inflammation, molecules such as corticotropin-releasing hormone (CRH) are released by MCs, which activate microglia cells and pro-inflammatory processes, suggesting that MCs are involved in stress-related neuroinflammation and neurodegeneration (45).

Mast cells in hypersensitivity reactions

MCs derive from the bone marrow and then migrate into peripheral tissues to mature. The maturation of MCs is dependent on microenvironmental conditions such as the presence of IL-3, IL-6, stem cell factor (SCF), and other growth factors released from activated T-cells (46,47). Activated mucosal MCs and those from bone marrow can secrete inflammatory proteins without degranulation. MCs which mature in the presence of IL-3 also express IL-2 receptors (48), and IL-2 additionally promotes the generation of lymphocyte-activated killer (LAK) cells, as well as CD8+ T cells and natural killer (NK) cell cytolytic activity (49).

Cytotoxic T cells that express CD8+ are the strongest effectors in the immune response against cancer (50), and the interaction between MCs and Tregs can influence the intensity of tumor-induced inflammation, resulting in the inhibition or promotion of the growth of tumors (51). Therefore, the MC-Treg relationship may offer useful therapeutic options for tumor immunotherapy.

Lymphocyte products, such as IL-1, can trigger or increase MC secretion (52,53), and the early release of MCs could be related to the delayed response of T-cells (54), a process that may be linked to allergic reactions which include a late phase component (55).

Studying the relationship between MCs and T-cells, and their possible regulation by neuroendocrine or tumor-generated substances, could provide the basis for new therapies.

The role of mast cells in tumor growth

As early as 1877, MCs were seen at tumor sites (56) and as time progressed, were subsequently suspected to be involved in the growth of tumors (57). It is now clear that these immune cells proliferate around tumors and in the tumor microenvironment during disease progression. The accumulation of MCs has been seen in a variety of tumors including epidermoid carcinoma (58), adenomatous polyps (59), rat mammary adenocarcinoma (60), pancreatic β -cell tumour (61), cervical carcinoma (62), and melanoma (63).

Tumor-secreted factors recruit and activate MCs, with the primary one being SCF (64). However, fibroblast growth factor (FGF)-2, vascular endothelial growth factor (VEGF), platelet-derived endothelial cell growth factor (PD-ECGF), RANTES, monocyte chemotactic protein (MCP)-1, adenosine, and adrenomedullin have also been seen to recruit and/or activate MCs to the tumor site (65-67).

MC accumulation is also correlated with vascularization, with increased numbers of MCs seen in highly vascularized areas of certain tumors (62,68,69). An association has also been reported between MC migration and new vessel formation in breast, colorectal, and uterine tumors (68,70,71). The perivascular location of MCs, and the fact that they can release vasoactive agents, links these immune cells to the support and maintenance of the vasculature and angiogenesis (72,73). Interestingly, MCs accumulate at tumor sites before new capillaries are formed (73). In fact, MCs contain and secrete mucopolysaccharide heparin, which causes capillary endothelial cell migration *in vitro* (74).

Numerous normal tissues produce a small amount of VEGF, but this process is tightly regulated, and the endothelial growth factors are minimally expressed in normal conditions (75), contrasting the high rate of expression that occurs in tumors where angiogenic factors appear to be continuously expressed (76). Tumor-derived peptides attract MCs to the tumor site where they can secrete heparin within the collagenous stroma (77). A track, or path, is formed behind the migrating MCs as they partially release this heparin, which could direct the movement of sprouting capillaries towards the direction of the tumor (74). Growth factors such as nerve growth factor (NGF) (78), as well as IL-1 produced by macrophages, which are abundant in proliferating tissues, induce MC degranulation.

Histamine from MCs can stimulate local cell proliferation, which has been seen by the rapid growth of cells neighboring to activated degranulated MCs (79). MC-derived histamine also activates T-suppressor cells, which can inhibit the immune system (80,81).

The antitumorigenic functions of mast cells

While MCs have effects that favor tumor growth and are associated with unfavorable prognosis, they also show inhibitive effects as well. In fact, MC infiltration at tumor sites has sometimes been associated with favorable prognosis. Studies have shown that the presence of MCs in some colon cancers such as colorectal cancer has positive effects and

increases survival (82-84). Additionally, MC infiltration has also been correlated with improved prognosis in prostate carcinoma (85) and breast carcinoma (86). Whether MCs have pro- or anti-tumorigenic effects against cancer could depend on the nature of local MC subsets and the particular stimuli within the tumor microenvironment (87).

MCs can have cytotoxic activity and recruit and activate immune cells at the tumor microenvironment. They can directly interact with tumor cells, release different mediators that modulate the immune response at the tumor microenvironment, and by producing cytokines and chemokines, recruit other immune cells to the tumor site (87). MCs have been seen to have a selective action against tumor cells, showing cytotoxic activity to tumor cells in a preferential manner that does not harm other cells, such as fibroblasts (88).

Serine proteases from basophils have cytotoxic actions against tumor cells, and MCs are a rich source of these proteases which are stored in large amounts in the cytoplasmic granules of MCs and are also released in the process of degranulation (89).

Further evidence with MC-deficient W/W^v mice has shown that tumor growth incidence is lower after subcutaneous treatment with 3-methylcholanthrene, when compared with normal congenital mice following the same treatment (88,90). When the carcinogen was given after the MC deficiency had been overcome by bone marrow transplantation, this increased tumor incidence was seen at normal levels (88,90).

Vasoactive amines that are released by MCs could also contribute to the modulation of the tumor microenvironment.

Studies have shown that late hypersensitivity reactions involving killer T-cells are dependent on the early MC secretion of certain vasoactive mediators (54), a process which could be vital for the immune system to launch an effective defense against cancer cells. T-cells that are recruited by MCs may then proceed to secrete cytokines, which further stimulate the secretion of MCs (91). Considering this, tumor cells may play a selective role in inhibiting or promoting the secretion of specific MC mediators. It has been reported that MCs located very close to growing tumor cells had been inhibited and were unresponsive to the regular secretagogues (92), and that certain polyamines found in growing tumor cells impede MC degranulation (93-95).

CONCLUSIONS

MCs are well known for their involvement in allergic reactions, but they are increasingly being implicated in other physiological and pathological conditions. In the brain, MCs partake in complex interactions with microglia and participate in neuroinflammation, effecting the permeability of the BBB and neurodegenerative processes such as neuronal death, excitotoxicity, and synaptic dysfunction. It is known that the nervous system, with the production of neuropeptides, can influence both tumor onset and growth. MCs, the immune elements that mediate both inflammation and the body's defense, play an important role in this stage. Neuropeptide-activated MCs can release proinflammatory molecules such as cytokines that aggravate the tumor state, while they can also produce molecules that oppose tumor growth. Further definition of the role of MCs is needed to uncover their actions in neuroimmunology and tumor growth, and to identify MC-targeted treatments.

Conflict of interest

The author declares that they have no conflict of interest.

REFERENCES

1. Steel JL, Geller DA, T. Clark Gamblin, Olek MC, Carr BI. Depression, Immunity, and Survival in Patients With Hepatobiliary Carcinoma. *Journal of clinical oncology*. 2007;25(17):2397-2405. doi:<https://doi.org/10.1200/jco.2006.06.4592>
2. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients. *Cancer*. 2009;115(22):5349-5361. doi:<https://doi.org/10.1002/cncr.24561>
3. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? *Nature Clinical Practice Oncology*. 2008;5(8):466-475. doi:<https://doi.org/10.1038/ncponc1134>
4. Eckerling A, Ricon-Becker I, Sorski L, Sandbank E, Ben-Eliyahu S. Stress and cancer: mechanisms, significance and future directions. *Nature Reviews Cancer*. 2021;21(12):767-785. doi:<https://doi.org/10.1038/s41568-021-00395-5>
5. Morey JN, Boggero IA, Scott AB, Segerstrom SC. Current directions in stress and human immune function. *Current Opinion in Psychology*. 2015;5(1):13-17. doi:<https://doi.org/10.1016/j.copsyc.2015.03.007>

6. Gouin JP, Glaser R, Malarkey WB, Beversdorf D, Kiecolt-Glaser J. Chronic stress, daily stressors, and circulating inflammatory markers. *Health Psychology*. 2012;31(2):264-268. doi:<https://doi.org/10.1037/a0025536>
7. Nemeroff CB. Psychoneuroimmunoendocrinology: The biological basis of mind-body physiology and pathophysiology. *Depression and Anxiety*. 2013;30(4):285-287. doi:<https://doi.org/10.1002/da.22110>
8. González-Díaz SN, Arias-Cruz A, Elizondo-Villarreal B, Monge-Ortega OP. Psychoneuroimmunoendocrinology: clinical implications. *The World Allergy Organization Journal*. 2017;10(1). doi:<https://doi.org/10.1186/s40413-017-0151-6>
9. Intebi A. The psychoneuroimmunoendocrinology and its importance in modern medicine. *Rev Méd-Cient "Luz Vida."* 2012;3(1):71-2.
10. Ortega MA, García-Montero C, Fraile-Martinez O, et al. Immune-Mediated Diseases from the Point of View of Psychoneuroimmunoendocrinology. *Biology*. 2022;11(7):973. doi:<https://doi.org/10.3390/biology11070973>
11. Dave ND, Xiang L, Rehm KE, Marshall GD. Stress and Allergic Diseases. *Immunology and Allergy Clinics of North America*. 2011;31(1):55-68. doi:<https://doi.org/10.1016/j.iac.2010.09.009>
12. Wright RJ. Alternative modalities for asthma that reduce stress and modify mood states: evidence for underlying psychobiologic mechanisms. *Annals of Allergy, Asthma & Immunology*. 2004;93(2):S18-S23. doi:[https://doi.org/10.1016/s1081-1206\(10\)61483-4](https://doi.org/10.1016/s1081-1206(10)61483-4)
13. Liu LY, Coe CL, Swenson CA, Kelly EA, Kita H, Busse WW. School examinations enhance airway inflammation to antigen challenge. *American Journal of Respiratory and Critical Care Medicine*. 2002;165(8):1062-1067. doi:<https://doi.org/10.1164/ajrccm.165.8.2109065>
14. Gauci M, King MG, Saxarra H, Tulloch BJ, Husband AJ. A Minnesota Multiphasic Personality Inventory profile of women with allergic rhinitis. *Psychosomatic Medicine*. 1993;55(6):533-540. doi:<https://doi.org/10.1097/00006842-199311000-00009>
15. Eva M.J. Peters, Liezmann C, Spatz K, et al. Nerve Growth Factor Partially Recovers Inflamed Skin from Stress-Induced Worsening in Allergic Inflammation. *Journal of Investigative Dermatology*. 2011;131(3):735-743. doi:<https://doi.org/10.1038/jid.2010.317>
16. Foreman JC. Neuropeptides and the pathogenesis of allergy. *Allergy*. 1987;42(1):1-11. doi:<https://doi.org/10.1111/j.1398-9995.1987.tb02180.x>
17. Ehrlich P: Beiträge zur Theorie und Praxis der histologischen Färbung (thesis, 1878); in: The Collected Papers of Paul Ehrlich. Elsevier, 2013, pp 29-64.
18. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. *The Journal of Immunology*. 1991;146(5):1410-1415. doi:<https://doi.org/10.4049/jimmunol.146.5.1410>
19. Rottem M, Okada T, Goff J, Metcalfe D. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI- cell population. *Blood*. 1994;84(8):2489-2496. doi:<https://doi.org/10.1182/blood.v84.8.2489.2489>
20. Kitamura Y, Ito A. Mast cell-committed progenitors. *Proceedings of the National Academy of Sciences*. 2005;102(32):11129-11130. doi:<https://doi.org/10.1073/pnas.0505073102>
21. Valent P, Spanblochl E, Sperr W, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. *Blood*. 1992;80(9):2237-2245. doi:<https://doi.org/10.1182/blood.v80.9.2237.2237>
22. Metcalfe DD. Mast cells and mastocytosis. *Blood*. 2008;112(4):946-956. doi:<https://doi.org/10.1182/blood-2007-11-078097>
23. Xu H, Shi X, Li X, et al. Neurotransmitter and neuropeptide regulation of mast cell function: a systematic review. *Journal of Neuroinflammation*. 2020;17(1). doi:<https://doi.org/10.1186/s12974-020-02029-3>
24. Germundson DL, Nagamoto-Combs K. Potential Role of Intracranial Mast Cells in Neuroinflammation and Neuropathology Associated with Food Allergy. *Cells*. 2022;11(4):738. doi:<https://doi.org/10.3390/cells11040738>
25. Chen F, Zhuang X, Lin L, et al. New horizons in tumor microenvironment biology: challenges and opportunities. *BMC Medicine*. 2015;13(1). doi:<https://doi.org/10.1186/s12916-015-0278-7>
26. Moon TC, Befus AD, Kulka M. Mast Cell Mediators: Their Differential Release and the Secretory Pathways Involved. *Frontiers in Immunology*. 2014;5. doi:<https://doi.org/10.3389/fimmu.2014.00569>

27. Van Loveren H, Kraeuter-Kops S, Askenase PW. Different mechanisms of release of vasoactive amines by mast cells occur in T cell-dependent compared to IgE-dependent cutaneous hypersensitivity responses. *European Journal of Immunology*. 1984;14(1):40-47. doi:<https://doi.org/10.1002/eji.1830140108>
28. Carraway RE, Cochrane DE, Granier C, Kitabgi P, Leeman EL, Singer EA. Parallel secretion of endogenous 5-hydroxytryptamine and histamine from mast cells stimulated by vasoactive peptides and compound 48/80. *British Journal of Pharmacology*. 1984;81(2):227-229. doi:<https://doi.org/10.1111/j.1476-5381.1984.tb10069.x>
29. Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H, et al. Neuroinflammation induces neurodegeneration. *Journal of neurology, neurosurgery and spine*. 2016;1(1):1003.
30. Gomez-Nicola D, Boche D. Post-mortem analysis of neuroinflammatory changes in human Alzheimer's disease. *Alzheimer's Research & Therapy*. 2015;7(1). doi:<https://doi.org/10.1186/s13195-015-0126-1>
31. Lagarde J, Sarazin M, Bottlaender M. In vivo PET imaging of neuroinflammation in Alzheimer's disease. *Journal of Neural Transmission*. 2017;125(5):847-867. doi:<https://doi.org/10.1007/s00702-017-1731-x>
32. Stojkowska I, Wagner BM, Morrison BE. Parkinson's disease and enhanced inflammatory response. *Experimental Biology and Medicine*. 2015;240(11):1387-1395. doi:<https://doi.org/10.1177/1535370215576313>
33. McCombe PA, Henderson RD. The Role of Immune and Inflammatory Mechanisms in ALS. *Current Molecular Medicine*. 2011;11(3):246-254. doi:<https://doi.org/10.2174/156652411795243450>
34. Silver R, Silverman AJ, Vitković L, Lederhendler II. Mast cells in the brain: evidence and functional significance. *Trends in Neurosciences*. 1996;19(1):25-31. doi:[https://doi.org/10.1016/0166-2236\(96\)81863-7](https://doi.org/10.1016/0166-2236(96)81863-7)
35. Jin Y, Silverman AJ, Vannucci SJ. Mast Cells Are Early Responders After Hypoxia-Ischemia in Immature Rat Brain. *Stroke*. 2009;40(9):3107-3112. doi:<https://doi.org/10.1161/strokeaha.109.549691>
36. Silver R, Curley JP. Mast cells on the mind: new insights and opportunities. *Trends in Neurosciences*. 2013;36(9):513-521. doi:<https://doi.org/10.1016/j.tins.2013.06.001>
37. Bugajski AJ, Chłap Z, Gadek-Michalska, Bugajski J. Effect of isolation stress on brain mast cells and brain histamine levels in rats. *Agents and actions*. 1994;41(S1):C75-C76. doi:<https://doi.org/10.1007/bf02007774>
38. Jones MK, Nair A, Gupta M. Mast Cells in Neurodegenerative Disease. *Frontiers in Cellular Neuroscience*. 2019;13. doi:<https://doi.org/10.3389/fncel.2019.00171>
39. Zhang S, Zeng X, Yang H, Hu G, He S. Mast Cell Tryptase Induces Microglia Activation via Protease-activated Receptor 2 Signaling. *Cellular Physiology and Biochemistry*. 2012;29(5-6):931-940. doi:<https://doi.org/10.1159/000171029>
40. Gupta K, Harvima IT. Mast cell-neural interactions contribute to pain and itch. *Immunological reviews*. 2018;282(1):168-187. doi:<https://doi.org/10.1111/imr.12622>
41. Metcalfe DD, Baram D, Mekori YA. Mast cells. *Physiological Reviews*. 1997;77(4):1033-1079. doi:<https://doi.org/10.1152/physrev.1997.77.4.1033>
42. Vukman KV, Försönits A, Oszvald A, Tóth EA, Buzás EI. Mast cell secretome: Soluble and vesicular components. *Seminars in Cell & Developmental Biology*. 2017;67:65-73. doi:<https://doi.org/10.1016/j.semcdb.2017.02.002>
43. Machado A, Herrera AJ, de Pablos RM, et al. Chronic stress as a risk factor for Alzheimer's disease. *Reviews in the Neurosciences*. 2014;25(6). doi:<https://doi.org/10.1515/revneuro-2014-0035>
44. Hoeijmakers L, Ruigrok SR, Amelanchik A, et al. Early-life stress lastingly alters the neuroinflammatory response to amyloid pathology in an Alzheimer's disease mouse model. *Brain, Behavior, and Immunity*. 2017;63:160-175. doi:<https://doi.org/10.1016/j.bbi.2016.12.023>
45. Kritas SK, Saggini A, Cerulli G, et al. Corticotropin-Releasing Hormone, Microglia and Mental Disorders. *International Journal of Immunopathology and Pharmacology*. 2014;27(2):163-167. doi:<https://doi.org/10.1177/039463201402700203>
46. Razin E, Ihle JN, Seldin DC, et al. Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. *Journal of immunology*. 1984;132(3):1479-1486. doi:<https://doi.org/10.4049/jimmunol.132.3.1479>
47. Nagata K, Nishiyama C. IL-10 in Mast Cell-Mediated Immune Responses: Anti-Inflammatory and Proinflammatory Roles. *International Journal of Molecular Sciences*. 2021;22(9):4972. doi:<https://doi.org/10.3390/ijms22094972>

48. Akula S, Paivandy A, Fu Z, Thorpe M, Pejler G, Hellman L. How Relevant Are Bone Marrow-Derived Mast Cells (BMMCs) as Models for Tissue Mast Cells? A Comparative Transcriptome Analysis of BMMCs and Peritoneal Mast Cells. *Cells*. 2020;9(9):2118. doi:<https://doi.org/10.3390/cells9092118>
49. Liao W, Lin JX, Leonard Warren J. Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy. *Immunity*. 2013;38(1):13-25. doi:<https://doi.org/10.1016/j.immuni.2013.01.004>
50. Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8 + T cells in cancer and cancer immunotherapy. *British Journal of Cancer*. 2020;124:359-367. doi:<https://doi.org/10.1038/s41416-020-01048-4>
51. Khazaie K, Blatner NR, Khan MW, et al. The significant role of mast cells in cancer. *Cancer and Metastasis Reviews*. 2011;30(1):45-60. doi:<https://doi.org/10.1007/s10555-011-9286-z>
52. Subramanian N, Bray M. Interleukin 1 releases histamine from human basophils and mast cells in vitro. *Journal of Immunology*. 1987;138(1):271-275. doi:<https://doi.org/10.4049/jimmunol.138.1.271>
53. Gallenga CE, Pandolfi F, Caraffa AI, et al. Interleukin-1 family cytokines and mast cells: activation and inhibition. *Journal of Biological Regulators and Homeostatic Agents*. 2019;33(1):1-6.
54. Askenase PW, Van Loverent H. Delayed-type hypersensitivity: activation of mast cells by antigen-specific T-cell factors initiates the cascade of cellular interactions. *Immunology Today*. 1983;4(9):259-264. doi:[https://doi.org/10.1016/0167-5699\(83\)90046-4](https://doi.org/10.1016/0167-5699(83)90046-4)
55. Kaliner MA. The Late-Phase Reaction and Its Clinical Implications. *Hospital Practice*. 1987;22(10):73-83. doi:<https://doi.org/10.1080/21548331.1987.11703334>
56. Ehrlich P. Beiträge zur Kenntniss der Anilinfärbungen und ihrer Verwendung in der mikroskopischen Technik. *Archiv für Mikroskopische Anatomie*. 1877;13(1):263-277. doi:<https://doi.org/10.1007/bf02933937>
57. Yoo D. Bone-Marrow Mast Cells in Lymphoproliferative Disorders. *Annals of Internal Medicine*. 1978;88(6):753. doi:<https://doi.org/10.7326/0003-4819-88-6-753>
58. Flynn EA, Schwartz JL, Shklar G. Sequential mast cell infiltration and degranulation during experimental carcinogenesis. *Journal of Cancer Research and Clinical Oncology*. 1991;117(2):115-122. doi:<https://doi.org/10.1007/bf01613134>
59. Gounaris E, Erdman SE, Restaino C, et al. Mast cells are an essential hematopoietic component for polyp development. *Proceedings of the National Academy of Sciences*. 2007;104(50):19977-19982. doi:<https://doi.org/10.1073/pnas.0704620104>
60. Dabbous MK, Walker R, Haney L, Carter LM, Nicolson GL, Woolley DE. Mast cells and matrix degradation at sites of tumour invasion in rat mammary adenocarcinoma. *British Journal of Cancer*. 1986;54(3):459-465. doi:<https://doi.org/10.1038/bjc.1986.198>
61. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. *Nature Medicine*. 2007;13(10):1211-1218. doi:<https://doi.org/10.1038/nm1649>
62. Hartveit F, Sandstad E. Stromal metachromasia: a marker for areas of infiltrating tumour growth? *Histopathology*. 1982;6(4):423-428. doi:<https://doi.org/10.1111/j.1365-2559.1982.tb02739.x>
63. Duncan LM, Richards LA, Mihm MC. Increased mast cell density in invasive melanoma. *Journal of Cutaneous Pathology*. 1998;25(1):11-15. doi:<https://doi.org/10.1111/j.1600-0560.1998.tb01683.x>
64. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. *PubMed*. 2000;60(23):6757-6762.
65. Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 Chemokines on In Vivo Basophilic Cell Recruitment in Rat Skin Injection Model and Their Role in Modifying the Protein and mRNA Levels for Histidine Decarboxylase. *Blood*. 1997;89(11):4120-4127. doi:<https://doi.org/10.1182/blood.v89.11.4120>
66. Zudaire E, Martínez A, Garayoa M, et al. Adrenomedullin Is a Cross-Talk Molecule that Regulates Tumor and Mast Cell Function during Human Carcinogenesis. *American Journal of Pathology*. 2006;168(1):280-291. doi:<https://doi.org/10.2353/ajpath.2006.050291>
67. Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I. Mast Cell-Mediated Stimulation of Angiogenesis. *Circulation Research*. 2003;92(5):485-492. doi:<https://doi.org/10.1161/01.res.0000061572.10929.2d>

68. Bowrey PF, King J, Magarey C, et al. Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? *British Journal of Cancer*. 2000;82(1):167-170. doi:<https://doi.org/10.1054/bjoc.1999.0895>
69. Svennevig JI. *In situ* identification of inflammatory cells in malignant, non-lymphoid human tumours. *Acta pathologica et microbiologica Scandinavica Section A Pathology*. 2009;88A(1-6):387-395. doi:<https://doi.org/10.1111/j.1699-0463.1980.tb02511.x>
70. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. *The Journal of Pathology*. 1999;189(4):487-495. doi:[https://doi.org/10.1002/\(sici\)1096-9896\(199912\)189:4%3C487::aid-path484%3E3.0.co;2-i](https://doi.org/10.1002/(sici)1096-9896(199912)189:4%3C487::aid-path484%3E3.0.co;2-i)
71. Graham R, Graham J. Mast cells and cancer of the cervix. *PubMed*. 1966;123(1):3-9.
72. Michailidou EZ, Markopoulos AK, Antoniadis DZ. Mast Cells and Angiogenesis in Oral Malignant and Premalignant Lesions. *The open dentistry journal*. 2008;2(1):126-132. doi:<https://doi.org/10.2174/1874210600802010126>
73. Kessler DA, Langer RS, Pless NA, Folkman J. Mast cells and tumor angiogenesis. *International Journal of Cancer*. 1976;18(5):703-709. doi:<https://doi.org/10.1002/ijc.2910180520>
74. Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. *Journal of Experimental Medicine*. 1980;152(4):931-944. doi:<https://doi.org/10.1084/jem.152.4.931>
75. Liao W, Zhu J, Zhang H, Cui Y, Peng Q. The relationship between vascular endothelial growth factor expression and the risk of childhood nephroblastoma: systematic review and meta-analysis. *Translational Pediatrics*. 2022;11(3):375-384. doi:<https://doi.org/10.21037/tp-21-593>
76. Pozzi A, Zent R. Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*. 2009;1(2):254-272. doi:<https://doi.org/10.1002/wsbm.7>
77. Poole TJ, Zetter BR. Stimulation of rat peritoneal mast cell migration by tumor-derived peptides. *PubMed*. 1983;43(12 Pt 1):5857-5861.
78. Kawamoto K, Aoki J, Tanaka A, et al. Nerve Growth Factor Activates Mast Cells Through the Collaborative Interaction with Lysophosphatidylserine Expressed on the Membrane Surface of Activated Platelets. *Journal of Immunology*. 2002;168(12):6412-6419. doi:<https://doi.org/10.4049/jimmunol.168.12.6412>
79. Garbuzenko E, Nagler A, Pickholtz D, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. *Clinical Experimental Allergy*. 2002;32(2):237-246. doi:<https://doi.org/10.1046/j.1365-2222.2002.01293.x>
80. Martin R, Saleem SJ, Folgosa L, et al. Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. *Journal of Leukocyte Biology*. 2014;96(1):151-159. doi:<https://doi.org/10.1189/jlb.5a1213-644r>
81. Slaga TJ, Scribner JD. Inhibition of Tumor Initiation and Promotion by Anti-Inflammatory Agents 2. *Journal of the National Cancer Institute*. 1973;51(5):1723-1725. doi:<https://doi.org/10.1093/jnci/51.5.1723>
82. Bodduluri SR, Mathis S, Maturu P, et al. Mast Cell–Dependent CD8+ T-cell Recruitment Mediates Immune Surveillance of Intestinal Tumors in ApcMin/+ Mice. *Cancer Immunology Research*. 2018;6(3):332-347. doi:<https://doi.org/10.1158/2326-6066.cir-17-0424>
83. Tan SY. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. *World Journal of Gastroenterology*. 2005;11(8):1210. doi:<https://doi.org/10.3748/wjg.v11.i8.1210>
84. Mehdawi LM, Osman J, Topi G, Sjölander A. High tumor mast cell density is associated with longer survival of colon cancer patients. *Acta Oncologica*. 2016;55(12):1434-1442. doi:<https://doi.org/10.1080/0284186x.2016.1198493>
85. Fleischmann A, Schlomm T, Köllermann J, et al. Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis. *The Prostate*. 2009;69(9):976-981. doi:<https://doi.org/10.1002/pros.20948>
86. Rajput AB, Turbin DA, Cheang MC, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. *Breast Cancer Research and Treatment*. 2007;107(2):249-257. doi:<https://doi.org/10.1007/s10549-007-9546-3>

87. Oldford SA, Marshall JS. Mast cells as targets for immunotherapy of solid tumors. *Molecular Immunology*. 2015;63(1):113-124. doi:<https://doi.org/10.1016/j.molimm.2014.02.020>
88. Farram E, Nelson DS. Mouse mast cells as anti-tumor effector cells. *Cellular Immunology*. 1980;55(2):294-301. doi:[https://doi.org/10.1016/0008-8749\(80\)90162-8](https://doi.org/10.1016/0008-8749(80)90162-8)
89. Hellman L, Akula S, Fu Z, Wernersson S. Mast Cell and Basophil Granule Proteases - In Vivo Targets and Function. *Frontiers in Immunology*. 2022;13. doi:<https://doi.org/10.3389/fimmu.2022.918305>
90. Tanooka H, Kitamura Y, Sado T, Tanaka K, Nagase M, Kondo S. Evidence for Involvement of Mast Cells in Tumor Suppression in Mice. *Journal of the National Cancer Institute*. 1982;69(6):1305-1309. doi:<https://doi.org/10.1093/jnci/69.6.1305>
91. Bulfone-Paus S, Bahri R. Mast Cells as Regulators of T Cell Responses. *Frontiers in Immunology*. 2015;6:394. doi:<https://doi.org/10.3389/fimmu.2015.00394>
92. Andersson AC, Stig Henningson, Lundell L, Rosengren E, Sundler F. Diamines and polyamines in DMBA-induced breast carcinoma containing mast cells resistant to compound 48/80. *Agents and actions*. 1976;6(5):577-583. doi:<https://doi.org/10.1007/bf01971572>
93. Theoharides TC. Polyamines spermidine and spermine as modulators of calcium-dependent immune processes. *Life Sciences*. 1980;27(9):703-713. doi:[https://doi.org/10.1016/0024-3205\(80\)90323-9](https://doi.org/10.1016/0024-3205(80)90323-9)
94. Vliagoftis H, Boucher W, Mak LL, Theoharides TC. Inhibition of mast cell secretion by oxidation products of natural polyamines. *Biochemical Pharmacology*. 1992;43(10):2237-2245. doi:[https://doi.org/10.1016/0006-2952\(92\)90183-j](https://doi.org/10.1016/0006-2952(92)90183-j)
95. García-Faroldi G, Rodríguez CE, Urdiales JL, et al. Polyamines Are Present in Mast Cell Secretory Granules and Are Important for Granule Homeostasis. Holowka D, ed. *PLoS ONE*. 2010;5(11):e15071. doi:<https://doi.org/10.1371/journal.pone.0015071>